XML 67 R53.htm IDEA: XBRL DOCUMENT v3.21.2
License Agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Feb. 28, 2018
USD ($)
Jan. 08, 2018
$ / shares
License agreements                
Long term investments   $ 192,096   $ 192,096   $ 222,301    
Research and development expense   334,945 $ 438,109 985,352 $ 1,809,997      
Unrealized gain (loss) on long term investments   (27,450) (13,207) (28,394) 10,935      
Syros Pharmaceuticals, Inc.                
License agreements                
Number of program targets | item 7              
Long term investments   $ 4,200   $ 4,200   $ 10,200    
Ownership percentage (as a percent)   2.00%   2.00%        
Unrealized gain (loss) on long term investments   $ (900) $ (1,700) $ (6,000) $ 1,800      
Syros Pharmaceuticals, Inc. | Stock purchase agreement                
License agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8              
Purchase price of common stock $ 10,000              
Per share price | $ / shares $ 12.61             $ 9.77
Lock-up period 12 months              
Discount for lack of marketability $ 100              
Fair value of shares on the issuance date 7,600              
Long term investments 7,600              
Research and development expense $ 2,400              
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement                
License agreements                
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1              
Purchase price of common stock $ 1,400              
Per share price | $ / shares $ 9.55              
Long term investments             $ 1,400  
Syros Pharmaceuticals, Inc. | Maximum                
License agreements                
Target selection and option exercise fee payment $ 54,000              
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum                
License agreements                
Additional milestone payments under the license agreement 50,000              
Syros Pharmaceuticals, Inc. | Sales and Commercial Milestones | Maximum                
License agreements                
Additional milestone payments under the license agreement $ 65,000